- $927.45m
- $718.55m
Annual income statement for Compass Therapeutics., fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.85 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 81.9 | 41.7 | 50.4 | 57.5 | 72.8 |
| Operating Profit | -81.9 | -41.7 | -50.4 | -56.6 | -72.8 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -82.2 | -39.2 | -42.5 | -49.4 | -66.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -82.2 | -39.2 | -42.5 | -49.4 | -66.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -82.2 | -39.2 | -42.5 | -49.4 | -66.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -82.2 | -39.2 | -42.5 | -49.4 | -66.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.31 | -0.374 | -0.335 | -0.359 | -0.422 |